OLEMA PHARMACEUTICALS INC

Olema Pharmaceuticals’ stock fell sharply premarket, dropping about 15% to $8.68 after AstraZeneca said the Phase‑3 SERENA‑4 study of camizestrant did not show a statistically significant improvement in progression‑free survival. The setback hits Olema particularly hard because its own SERD/CERAN candidate palazestrant (OP‑1250) has a similar mechanism of action and is being tested in the Phase‑3 OPERA‑01 trial in an overlapping patient population. Stifel cut its price target for Olema significantly from $48 to $30 but kept its “Buy” rating. A weak market environment and biotech stocks already under pressure amplified the sell‑off; OPERA‑01 topline data remain an important future catalyst. » Mais em de.investing.com

At the Citigroup Biopharma Summit, Olema Oncology said that the topline data from the Phase III OPERA-01 study are now expected in the first quarter of 2027 rather than in the second half of 2026 due to slower recruitment in the ESR1 mutation cohort. The study is fully recruited and randomized; management continues to express confidence in palazestrant based on Phase II results and pegs OPERA-01’s market potential at about $5 billion annually. Meanwhile, OPERA-02 (combination with ribociclib) is enrolling well, and Olema is advancing OP-3136 (a KAT6 inhibitor) in collaboration with Bayer, with combination data expected in H1 2027. The company plans a lean U.S. launch with under 100 field sales representatives if data are positive and is using AI tools to support regulatory and operational processes. » Mais em de.investing.com

Olema Pharmaceuticals has appointed Dr. Prakash Raman to its board of directors. Raman brings more than 20 years of experience in leadership and business development roles in the biopharma industry, most recently as CEO of InduPro Therapeutics and previously in senior positions at Ribon Therapeutics, Flagship Pioneering and Novartis. Olema is advancing palazestrant in two Phase-3 studies and developing the KAT6 inhibitor OP-3136; the stock currently trades at $14.14 with a market capitalization of about $1.27 billion. » Mais em de.investing.com